Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dublin, March 14, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/rzqnm9/selfinjectable) has announced the addition of the "Self-injectable Specialty Drugs to 2022" report to their offering.
This comprehensive report examines the global self-injectable specialty drugs market and the drivers, challenges and opportunities set to face this market in the coming years.
Increases in life expectancy are expected to result in a growing number of patients diagnosed with chronic conditions. To counteract the financial and logistical implications of this trend, pressure from public health and managed care organizations will place a premium on therapeutic self-administration Specialty Injectable formulation and packaging decisions are increasingly being based on the results of human engineering inputs and patient preference research. Branding and packaging choices are more frequently being driven by data sources historically employed by consumer product marketers. For drug developers and device suppliers, the implications of these trends are influencing product development methodology and changing supply chain relationships.
Questions Answered:
- What are the currently marketed specialty injectable drugs intended for patient self administration?
- What are the therapeutic demand drivers for self-injectable specialty drugs and what are their growth prospects?
- What are the key formulation and packaging factors and market development issues for self-administered specialty injectables?
- What does the current self-injectable specialty drug market look like, who are the market leaders, and what will this market look like in 2022?
- What are the important therapeutic market segments for self-injectable specialty drugs, how large are they, and how fast are they growing?
- How important are pharma-device alliances and design partnerships in this market segment?
- What is the impact of economic, technology, and regulatory factors in this market?
Report Structure:
1. Self-Injectable Specialty Drug Market Dynamics
2. Self-injectable Delivery Device Selection Criteria
3. Self-injectable Specialty Drugs - Device Categories
4. Self-injectable Specialty Drugs - Product Analysis, Therapeutic
5. Company Profiles
For more information visit http://www.researchandmarkets.com/research/rzqnm9/selfinjectable
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infusions and Injectables
